<DOC>
	<DOC>NCT03066011</DOC>
	<brief_summary>The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).</brief_summary>
	<brief_title>Registry of Patients Treated With Systemic Mold-Active Triazoles</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Patients initiating one of the following target drugs: isavuconazonium sulfate (ISAV), voriconazole (VORI), posaconazole (POSA). Patients may be enrolled within 60 days from the time of treatment initiation. Currently enrolled in any clinical trial with an investigational antifungal agent. Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable. Retrospective patients who died before entering the study. Patients who previously participated in this registry.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mold-active triazoles</keyword>
</DOC>